Allergen Immunotherapy (AIT) with Subcutaneous Immunotherapy (SCIT)

This LCD covers subcutaneous allergen immunotherapy (SCIT) using specified aeroallergens (select tree/grass/weed pollens, cat/dog dander, D. pteronyssinus/D. farinae dust mites, certain molds, cockroach) for allergic rhinitis, conjunctivitis, allergic asthma, and dust‑mite atopic dermatitis, and excludes sublingual immunotherapy (including liquid SLIT), SCIT in pregnancy, non‑aeroallergen indications (e.g., venoms), food allergy treatments, and AD not due to dust mites. Coverage requires documented clinically relevant specific IgE (skin or serum), symptoms on natural exposure or a compatible temporal pattern, prior inadequate response/intolerance to pharmacotherapy or avoidance (≥28 days; ≥90 days for dust‑mite AD), physician examination and antigen preparation, administration under physician supervision in a facility equipped for anaphylaxis, regular monitoring (every 6–12 months) and documented clinical benefit within 12–24 months (otherwise discontinue/no reimbursement).